LC
PVLA

Lindbrook Capital’s Palvella Therapeutics PVLA Stock Holding History

Lindbrook Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15
Closed -$5K – 2637
2021
Q4 		$5K Sell
15
-10
-40% -$3.2K ﹤0.01% 1536
2021
Q3 		$10K Sell
25
-50
-67% -$17.4K ﹤0.01% 1008
2021
Q2 		$23K Sell
75
-50
-40% -$11K 0.01% 739
2021
Q1 		$26K Buy
+125
New +$27.3K 0.01% 667
2020
Q4 		– Sell
-19
Closed -$3.95K – 1898
2020
Q3 		$3K Hold
19
– – ﹤0.01% 1326
2020
Q2 		$5K Hold
19
– – ﹤0.01% 1111
2020
Q1 		$3K Sell
19
-100
-84% -$25.2K ﹤0.01% 1234
2019
Q4 		$34K Buy
119
+19
+19% +$5.27K 0.01% 562
2019
Q3 		$27K Hold
100
– – 0.01% 620
2019
Q2 		$37K Buy
+100
New +$29.8K 0.01% 511

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's PVLA Position: Q1 2022 in Review

Lindbrook Capital sold out of Palvella Therapeutics (PVLA) in Q1 2022, closing a stake of 15 shares — an estimated $5K sold.

Lindbrook Capital first reported a position in PVLA in Q2 2019 and held it in 10 quarters. The position peaked at $37K in Q2 2019. 71 funds tracked by Wall St. Rank hold PVLA as of Q1 2022.

  • Lindbrook Capital reported no remaining Palvella Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Lindbrook Capital sold 15 Palvella Therapeutics shares in Q1 2022, an estimated $5K.
  • Lindbrook Capital first reported a position in Palvella Therapeutics in Q2 2019 and held it in 10 quarters.
  • Lindbrook Capital's Palvella Therapeutics position peaked at $37K in Q2 2019.
  • 71 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2022.

Based on Lindbrook Capital's 13F filing for Q1 2022, filed 21 Apr 2022.